Oppenheimer Raised its Price Target on Prothena Corporation to $100 from $90
<p>Analysts at Oppenheimer increased their price target on <a href='https://financialmodelingprep.com/financial-summary/PRTA'>Prothena Corporation plc (NASDAQ:PRTA) to $100 from $90, as they refresh their favorable outlook on the company due to the recent update of FDA's Surrogate Endpoint Table, which now includes a reduction in amyloid-ß plaque for mAbs in mild-AD patients as appropriate for accelerated approval. </p>
<p>The analysts see confirmation that the company should benefit from regulatory precedence plus BIIB's launch efforts, noting that BIIB's Aduhelm was approved based on this surrogate endpoint. </p>

NASDAQ:PRTA